TY - JOUR T1 - Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 5221 LP - 5227 DO - 10.21873/anticanres.14525 VL - 40 IS - 9 AU - YUEH PAN AU - YA-HSU CHIU AU - SHAO-CHIH CHIU AU - DER-YANG CHO AU - LIANG-MING LEE AU - YU-CHING WEN AU - JACQUELINE WHANG-PENG AU - CHI-HAO HSIAO AU - PING-HSIAO SHIH Y1 - 2020/09/01 UR - http://ar.iiarjournals.org/content/40/9/5221.abstract N2 - Background/Aim: Bladder cancer (BLCA, urothelial bladder cancer) is one of the most common malignancies with increasing incidence and mortality worldwide. Poor diagnosis and the limitation of treatment is still an unmet need in clinical practice. γδ T-Cells have been paid increasing attention because of their potent cytotoxicity against tumors. Herein, we investigated the cytolytic effect of γδ T-cells in combination with the chemotherapeutic drug, carboplatin, against BLCA cells. Materials and Methods: The standard protocol for the induction and expansion of peripheral blood mononuclear cell-derived γδ T-cells was a zoledronic acid/interleukin-2-based medium system for 2 weeks. The cytotoxicity of γδ T-cells with and without carboplatin against BLCA cells was examined. Results: After incubation, T-cell receptor-positive γδ T-cells showed a natural killer cell-like phenotypic characteristic and dose-dependently increased cytotoxicity against BLCA cells. Interestingly, we found that in advanced BLCA cells, which were more resistant to carboplatin, the cell viability was significantly (p<0.05) reduced in the presence of γδ T-cells. Conclusion: Our findings showed that γδ T-cell therapy has potent benefit in cancer treatment. ER -